Recordati Rare Diseases

Recordati Rare Diseases company information, Employees & Contact Information

At Recordati Rare Diseases, we focus on the few - those affected by rare diseases. We believe that every single patient has the right to the best possible treatment. Patients with rare diseases are our top priority. They are at the core of our planning, our thinking and our actions. Social Media Guidelines: http://www.recordatirarediseases.com/social-media

Company Details

Employees
358
Founded
-
Address
70, Avenue Du Général De Gaulle, Immeuble Le Wilson,japan
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Puteaux, Île-de-France
Looking for a particular Recordati Rare Diseases employee's phone or email?

Recordati Rare Diseases Questions

News

Recordati Rare Diseases touts new data in Cushing’s syndrome - The Pharma Letter

Recordati Rare Diseases touts new data in Cushing’s syndrome The Pharma Letter

RECORDATI RARE DISEASES: CARBAGLU® (Carglumic Acid) Tablets 200mg Receives U.S. FDA Approval for a New Indication to Treat Acute Hyperammonemia Associated with Propionic Acidemia and Methylmalonic Acidemia - PR Newswire

RECORDATI RARE DISEASES: CARBAGLU® (Carglumic Acid) Tablets 200mg Receives U.S. FDA Approval for a New Indication to Treat Acute Hyperammonemia Associated with Propionic Acidemia and Methylmalonic Acidemia PR Newswire

Cystadrops Approved to Treat Corneal Crystal Deposits in Cystinosis - Medical Professionals Reference

Cystadrops Approved to Treat Corneal Crystal Deposits in Cystinosis Medical Professionals Reference

Recordati Rare Diseases Announces Availability of CYSTADROPS® (Cysteamine Ophthalmic Solution) 0.37% in the U.S. - PR Newswire

Recordati Rare Diseases Announces Availability of CYSTADROPS® (Cysteamine Ophthalmic Solution) 0.37% in the U.S. PR Newswire

Recordati Rare Diseases Announces First European Launch of Isturisa® (osilodrostat) - NTB Kommunikasjon

Recordati Rare Diseases Announces First European Launch of Isturisa® (osilodrostat) NTB Kommunikasjon

Recordati Rare Diseases Partners With the National Urea Cycle Disorders Foundation To Increase Awareness of the Risks of Hyperammonemia - PR Newswire

Recordati Rare Diseases Partners With the National Urea Cycle Disorders Foundation To Increase Awareness of the Risks of Hyperammonemia PR Newswire

Recordati: Isturisa® (Osilodrostat) Approved In The U.S. - PR Newswire

Recordati: Isturisa® (Osilodrostat) Approved In The U.S. PR Newswire

Top Recordati Rare Diseases Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant